Here are 13 featured spin-offs already underway and potential spin-offs that could be seen in 2017 and into 2018 that could radically change how Wall Street and Main Street evaluate companies ahead.
At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.
These four top companies all have data that could move the shares the rest of this year and into 2018. All have been around for years and will remain sector leaders for…
With Eli Lilly making a huge headline investment in a cancer vaccine, 24/7 Wall St. wanted to look under the hood to see what this deal really entails.
Jon C. Ogg The September 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The top analyst upgrades, downgrades and other research calls from Tuesday include Alphabet, Check Point Software, Chesapeake Energy, Chevron, Intel, MannKind, Schlumberger and Transocean.
The September 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer's disease.
The top analyst upgrades, downgrades and other research calls from Friday include AbbVie, Bristol-Myers, Eli Lilly, First Solar, Generac, Oracle, Sirius XM, Southwest and Wendy's.
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Eli Lilly is cutting about 8% of its global workforce in a "streamlining and focusing" effort as part of a cost structure initiative.
Jon C. Ogg The August 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks dropped.
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The top analyst upgrades, downgrades and other research calls from Wednesday include BP, Chipotle, Citigroup, Electronic Arts, Eli Lilly, McDonald's, Texas Instruments and U.S. Steel.
The July 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
